That FMC Corporation (FMC) is facing a challenging time would be an understatement, considering that its stock has lost 86% over the last five years. Meanwhile, FMC stock has shown some signs of life, and while it is still in the red for the year, it has rebounded 30% from its 2026 lows. In my previous article, I noted that FMC was a buy, albeit a risky one. With the stock now up significantly from those levels, let’s explore whether it remains attractive.
www.barchart.comTo begin, let’s look at some of the challenges FMC is facing. On a structural level, FMC has lost patent protection on some of its most profitable, higher-margin flagship chemicals, particularly the insecticide ingredient Rynaxypyr, which is leading to higher competition from generics and, by extension, pricing pressure. FMC’s balance sheet is also quite stretched, and it had a net debt (gross debt minus cash) of $3.8 billion at the end of June, which, for context, is nearly 2.5x the company’s market capitalization. The net debt-to-trailing 12-month earnings before interest, tax, depreciation, and amortization (EBITDA) multiple is 5.1x, which is again too high for comfort.
More Yield, Less Trap: Sign up free to get Barchart’s daily Dividend Investor newsletter straight to your inbox.
FMC Is Facing a Perfect Storm
FMC has faced additional headwinds this year. Crop prices have been weak, while input costs, particularly fertilizers and fuel, have risen sharply this year. According to FMC, buyers have been cautious, are cutting discretionary expenses, and are responding by either shifting to cheaper generics or reducing the number of applications. Notably, such behaviors are not limited to the agriculture industry, and several other companies have highlighted that buyers—both retail and corporate—are reconsidering their discretionary expenses.
Climate change is also not helping FMC’s cause, and it pointed to excessive heat in the Europe, the Middle East, and Africa (EMEA) region for lower-than-expected sales in Q2 2026. FMC’s portfolio is heavily tilted towards insecticides, and per the company’s proprietary Arc Farm Intelligence insect monitoring platform, the insect pressure is lower this year. This is a bigger headwind for FMC than for most competitors who have a healthy mix of herbicides and fungicides in their portfolios.
What's Its Turnaround Plan?
FMC has taken various measures to turn around the business. It is exiting uncompetitive ingredients and formulation production assets and shifting production to low-cost sources in Asia, which would lower its cost base. The company is also working on several new molecules, which would help enhance its revenues over the medium to long term. On a similar note, FMC has secured registration of Isoflex active in the EU and expects a launch next year.
It is deleveraging its balance sheet and has secured a $400 million equity investment from the Tessenderlo Group earlier this year while announcing a $114 million property sale-leaseback in Newark, Delaware. The company has signed a licensing agreement with Corteva for its rimisoxafen technology, as part of which Corteva would make an initial prepayment of $200 million.
It has announced the sale of its India business for $252 million and is working on disposing of a few of the smaller assets in its portfolio. FMC expects its net debt to fall to $2.6 billion by the end of this year as it progresses on the deleveraging initiatives. While that number would still be high for comfort, it is still a lot better compared to where things stood at the end of June.
FMC Stock Forecast
After FMC’s Q2 earnings release, several brokerages, including JPMorgan Chase, RBC, and Morgan Stanley, lowered their target prices. The overall Street sentiment remains bearish, with only four of the 18 analysts polled by Barchart rating FMC as a “Buy” equivalent. Twelve analysts rate FMC as a “Hold” while the remaining two rate it a “Strong Sell.” FMC stock’s mean target price of $14.07 is around 9% higher than the current price.
www.barchart.comWill FMC Cut Its Dividend?
Last year, FMC cut its quarterly dividend from 58 cents to only 8 cents but still boasts a dividend yield of almost 2.5%, thanks to the fall in its stock price. FMC’s annual cash outflow towards dividends is under $50 million, which I would say is not insignificant for the company given its precarious financial position. Responding to a question about a possible dividend cut to preserve cash, CEO Pierre R. Brondeau said during the Q2 2026 earnings call that it is “certainly a topic we will have with the Board and continue to have with the Board.” He, however, stressed, “absolutely no decision has been taken at this stage.”
That said, I don’t expect a dividend suspension at least this year, as the company expects 2026 to be a “trough” for its business, and cutting dividends won't really align with that assertion. However, if the company's turnaround plans don't yield the expected results by next year, a dividend cut/suspension might be on the table.
Should You Buy FMC Stock?
I believe that after the rise from the 2026 lows, FMC’s risk-reward doesn't look too attractive. The stock trades at a forward price-to-earnings (P/E) multiple of 10.24x, which, while not exorbitant, is not tempting enough to buy FMC here. Management has a lot on its plate for 2027 at a time when the macro environment is far from perfect. Overall, I see the recent rise as an opportunity to exit FMC, even though I would keep the stock on my radar for any meaningful changes in its business.
On the date of publication, Mohit Oberoi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
This Dividend Stock Is Facing a Perfect Storm. It Could Be the Time to Press that “Sell” Button Altria Is Spending More on Capex Than Any Other Consumer Staples Name. It’s a Calculated Sign of Strength. Eli Lilly vs. Novo Nordisk: One Has 39% Upside. I'm Picking the Other. Equinix Is Doubling Down on AI Data Centers. How to Play EQIX Stock Here